Skip to main content
SpringerLink
Log in

Meloxicam

  • New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Summary

▴ Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis

▴ It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory response, than against the constitutive form of this enzyme (COX-1), inhibition of which is associated with gastric, renal and other adverse effects

▴ It has anti-inflammatory effects similar to or better than those of other NS AIDs in animal models, and a greater therapeutic ratio (ulcerogenic potential: efficacy in adjuvant arthritis)

▴ In healthy volunteers meloxicam 7.5 or 15mg caused less gastrointestinal mucosal damage on endoscopy than piroxicam 20mg, with a significant difference between meloxicam 7.5mg and piroxicam

▴ In comparative clinical trials, meloxicam was at least as effective as piroxicam and naproxen in patients with rheumatoid arthritis, and diclofenac and piroxicam in patients with osteoarthritis

▴ Meloxicam was at least as well tolerated as piroxicam, diclofenac or naproxen overall but had improved gastrointestinal tolerability compared with these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1–10

    Article  PubMed  CAS  Google Scholar 

  2. Engelhardt G, Bögel R, Schnitzler C, et al. Meloxicam: a new NSAID with an improved safety profile through preferential inhibition of COX-2. Biochem Pharmacol 1996; 51: 21–8

    Article  PubMed  CAS  Google Scholar 

  3. Churchill L, Graham A, Shih C-K, et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Boehringer In-gelheim. (Data on file)

  4. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs — COX-2 enzyme inhibitors. Lancaster: Kluwer Academic Publishers. In press

  5. Pargellis CA, Rogers S, Pav S. Inhibition of prostaglandin H synthase by meloxicam. Boehringer Ingelheim. (Data on file)

  6. Rainsford KD, Ying C, Gadd SJ. Pharmacology of meloxicam compared with other NSAIDS at inflamed sites: effects on cartilage proteoglycan metabolism, synovial production of prostaglandins and interleukins, and polymorph oxyradicals. Boehringer Ingelheim. (Data on file)

  7. Bassleer C, Franchimont P. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Boehringer Ingelheim. (Data on file)

  8. Engelhardt G, Bögel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism. In vitro and in vivo findings — part 2. Biochem Pharmacol 1996; 51: 29–38

    Article  PubMed  CAS  Google Scholar 

  9. Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423–33

    Article  PubMed  CAS  Google Scholar 

  10. Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the rat. Inflamm Res 1995; 44: 548–5

    Article  PubMed  CAS  Google Scholar 

  11. Mohr W, Lehmann H. Chondroneutrality of meloxicam in spontaneously occurring osteoarthrosis in rats and mice. Boehringer Ingelheim. (Data on file)

  12. Stichtenoth DO, Wagner B, Tsikas D, et al. Meloxicam does not inhibit platelet aggregation and renal prostaglandin E2 synthesis in healthy volunteers. Boehringer Ingelheim. (Data on file)

  13. Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br J Rheumatol. In press

  14. Busch U, Engelhardt G. Distribution of [14C]meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 1990; 16_(2): 49–52

    Google Scholar 

  15. Türck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1996; 15: 23–30

    Google Scholar 

  16. Schmid J, Busch U, Heinzel G, et al. Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995; 23(11): 1206–13

    PubMed  CAS  Google Scholar 

  17. Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions 1991 Jan; 32: 52–3

    Article  PubMed  CAS  Google Scholar 

  18. Türck D, Busch U, Heinzel G, et al. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995 May; 9: 270–6

    Article  Google Scholar 

  19. Narjes H, Türck D, Busch U, et al. Tolerability and pharmacokinetics of meloxicam after i.m. administration. Boehringer Ingelheim. (Data on file)

  20. Busch U, Heinzel G, Narjes H, et al. Pharmacokinetics of meloxicam in patients with hepatic cirrhosis in comparison to healthy volunteers. Clin Drug Invest. In press

  21. Türck D, Schwarz A, Höffler D, et al. The pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis. A comparison with healthy volunteers. Boehringer Ingelheim. (Data on file)

  22. Degner F, Heinzel U, Busch G, et al. Transsynovial kinetics of meloxicam [abstract]. Scand J Rheumatol 1994 Suppl. 98: 121

    Google Scholar 

  23. Huskisson EC, Ghozlan R, Kurthen R, et al. A long term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol. In press

  24. Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal antiinflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48: 269–72

    Article  PubMed  CAS  Google Scholar 

  25. Busch U, Heinzel G, Narjes H, et al. Investigation of the interaction of meloxicam with Cimetidine, Maalox or aspirin. J Clin Pharmacol. In press

  26. Müller FO, Schall R, de Vaal AC, et al. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48: 247–51

    Article  PubMed  Google Scholar 

  27. Degner FL, Heinzel G, Narjes H, et al. The effect of meloxicam on the pharmacokinetics of β-acetyl-digoxin. Br J Clin Pharmacol 1995; 40: 486–8

    Article  PubMed  CAS  Google Scholar 

  28. Hübner G, Sander O, Degner F, et al. Lack of pharmacokinetic interaction of meloxicam with methotrexate in RA patients [abstract]. Scand J Rheumatol 1994 Suppl. 98: 108

    Google Scholar 

  29. Auvinet B, Ziller R, Appelboom T, et al. A comparison of the onset and intensity of action of meloxicam ampoules and meloxicam capsules in sciatica. Clin Ther 1995; 17: 1078–90

    Article  PubMed  CAS  Google Scholar 

  30. Colberg K, Hettich M, Sigmund R, et al. The efficacy and tolerability of an 8 day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Boehringer Ingelheim. (Data on file)

  31. Lemmel EM, Bolten W, Bourgos-Vargas R, et al. A doubleblind, randomized placebo controlled trial to evaluate the efficacy and safety of meloxicam 7.5 mg and 15 mg once daily in patients with rheumatoid arthritis. Boehringer Ingelheim. (Data on file)

  32. Huskisson EC, Narjes H, Bluhmki E. A 3 week double blind, randomized multicentre trial comparing the efficacy and tolerability of meloxicam, a new NSAID, in daily doses of 15 and 30 mg with piroxicam 20 mg in patients with rheumatoid arthritis. Boehringer Ingelheim. (Data on file)

  33. Wojtulewski JA, Schattenkirchner M, Barceló P, et al. A six months double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol. In press

  34. Ghozlan PR, Bernhardt M, Vélicitat P, et al. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br J Rheumatol. In press

  35. Lund B, Distel M, Bluhmki E. A double-blind randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Boehringer Ingelheim. (Data on file)

  36. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a six-months, double-blind comparison with diclofenac sodium. Br J Rheumatol. In press

  37. Goei Thé H, Lund B, Distel M, et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Boehringer Ingelheim. (Data on file)

  38. Lindén b, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol. In press

  39. Hosie J, Distel M, Bluhmki E. A six months double-blind study to compare the efficacy, safety and tolerability of meloxicam and piroxicam in patients with osteoarthritis of the hip or knee. Boehringer Ingelheim. (Data on file)

  40. Bird HA, Bevis PJR, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatoid disease and mild renal impairment. Br J Rheumatol. In press

  41. Distel M, Mueller C, Bluhmki E, et al. Global analysis of safety of a new NSAID, meloxicam. Br J Rheumatol. In press

  42. Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved. Arthritis Rheum 1988; 31: 1450–1

    Article  Google Scholar 

  43. Vane JR. NSAIDS, cox-2 inhibitors, and the gut. Lancet 1995 Oct 21; 346: 1105–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Stuart Noble & Julia A. Balfour

Authors
  1. Stuart Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia A. Balfour
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noble, S., Balfour, J.A. Meloxicam. Drugs 51, 424–430 (1996). https://doi.org/10.2165/00003495-199651030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651030-00007

Keywords

Search

Navigation